Cure8 research brief
Curcumin is a common dietary compound that reaches the colon and may interact with gut bacteria and host immune and barrier pathways implicated in IBD. Understanding these interactions could inform dietary approaches or adjunctive strategies for people with IBD.
Adult patients with IBD interested in dietary or complementary approaches, clinicians advising on diet and supplements, and researchers studying the microbiome–host interface or developing microbiota-targeted therapies.
This review article summarizes current evidence about curcumin (from turmeric) and its interactions with the gut microbiota and host pathways relevant to inflammatory bowel disease (IBD).
It focuses on curcumin's gastrointestinal fate, microbial biotransformation to more stable metabolites, bidirectional effects between curcumin and microbial ecology (including impacts on short-chain fatty acids, bile acids, and tryptophan-derived indoles), and downstream host signalling linked to barrier integrity, NF-κB/MAPK, immune cell polarization, and redox-sensitive programmes such as Nrf2 and ferroptosis.
The paper also discusses food-grade formulations and delivery approaches to increase colonic exposure and highlights research priorities including responder stratification and standardized biomarkers. Structured content depth: abstract (summary is grounded in the article abstract).
This article is a narrative review/summary (structured content depth: abstract). It synthesizes preclinical and clinical evidence but does not report new trial results. Curcumin has low systemic bioavailability and is extensively transformed by gut microbes; formulation and individual microbiota differences affect exposure and response.
Reviews do not replace clinical trials—evidence quality and clinically meaningful benefits for IBD need careful evaluation.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This review pools available human and animal studies on sodium butyrate for ulcerative colitis and highlights promising signals—especially for oral microencapsulated formulations—while noting that clinical evidence is...
This review highlights probiotic and synbiotic approaches centered on L. plantarum that aim to rebalance gut microbiota and support the intestinal barrier—areas of direct interest to people with IBD seeking adjunctive,...
The review proposes a low-cost, non-immunosuppressive adjunctive strategy targeting the gut microbiome and luminal metabolism to help maintain remission in UC, an area of strong patient interest but limited clinical...
